Fibroblast-Derived ECM as a Donor-Specific Pro-Osteogenic Coating Surpassing ASC- and Osteoblast-Derived ECM

Area of Science:

• Biomaterials Science
• Tissue Engineering
• Regenerative Medicine

Background:

• Large bone defects pose significant clinical challenges, with current treatments often lacking biological efficacy.
• Cell-deposited extracellular matrix (CD-ECM) offers a promising approach to enhance implant bioactivity by mimicking native tissue.
• Optimizing CD-ECM composition and bioactivity is crucial for improving bone regeneration outcomes.

Purpose of the Study:

• To compare the osteogenic potential of CD-ECMs derived from different cell sources: adipose tissue-derived mesenchymal stromal cells (ASCs), ASC-derived osteoprogenitor cells, and dermal fibroblasts.
• To investigate the impact of dextran sulfate (Dx-S) on ECM deposition and osteogenic properties.
• To evaluate the efficacy of fibroblast-derived ECM (Fibro-ECM) in supporting skeletal stem cell (SSC) osteogenesis for bone regeneration applications.

Main Methods:

• Comparative analysis of ECM composition (collagen, glycosaminoglycans) from different cell types.
• Assessment of CD-ECM's ability to support SSC proliferation and osteogenic differentiation.
• Production of CD-ECM on 3D scaffolds and enhancement using dextran sulfate treatment.
• Evaluation of fibroblast-derived ECM (Fibro-ECM) for bone regeneration potential.

Main Results:

• Fibro-ECM exhibited higher collagen and glycosaminoglycan content compared to ASC-derived ECMs.
• Only Fibro-ECM significantly supported SSC osteogenesis, enhancing proliferation and differentiation.
• Dextran sulfate treatment increased ECM deposition and osteogenic potential in fibroblasts.
• Fibroblasts produced more ECM with a stronger pro-osteogenic effect than ASCs or osteoprogenitor cells.

Conclusions:

• Dermal fibroblasts are a superior source for producing bioactive CD-ECM for bone regeneration compared to ASCs or osteoprogenitor cells.
• Fibro-ECM, particularly when enhanced with dextran sulfate, represents a promising strategy to improve the biological performance of bone regeneration implants.
• This study highlights the potential of engineered Fibro-ECM to address the biological limitations of current bone defect treatments.